

General Strategy for the Synthesis of Antirhine Alkaloids: Divergent Total Syntheses of (\pm)-Antirhine, (\pm)-18,19-Di- hydroantirhine, and Their 20-Epimers

Cheolwoo Bae,^{a,†} Eunjoon Park,^{a,†} Cheon-Gyu Cho,^b Cheol-Hong Cheon^{a,*}

^a Department of Chemistry, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea

^b Department of Chemistry, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea

Table of Contents


1. General Information-----	S2
2. Synthesis of Tetracyclic Core Structure (18)-----	S3
3. Total Synthesis of (\pm)-20- <i>epi</i> -Antirhine (3) and (\pm)-20- <i>epi</i> -18,19-Dihydroantirhine (4)-----	S7
4. Total Synthesis of (\pm)-Antirhine (1) and (\pm)-18,19-Dihydroantirhine (2)-----	S10
5. Plausible Transition State for Alkylation of Enolate 25 -----	S14
6. References -----	S16
7. Spectroscopic Data -----	S17

1. General Information

All reactions were carried out in an oven-dried glassware under an argon atmosphere unless otherwise noted. Except as otherwise indicated, all reactions were magnetically stirred and monitored by analytical thin layer chromatography (TLC) using pre-coated silica gel glass plates (0.25 mm) with F254 indicator. Visualization was accomplished by UV light (254 nm). Flash column chromatography was performed using silica gel 60 (230 – 400 mesh). Yields refer to chromatographically and spectroscopically pure compounds, unless otherwise noted. (E)-ethyl 2-aminocinnamate **9** was prepared by the reported procedures.¹ ¹H NMR and ¹³C NMR spectra were recorded on 500 MHz and 125 MHz spectrometers, respectively. Residual NMR solvents (CDCl₃ (δ_{H} : 7.26 ppm, δ_{C} : 77.16 ppm) were used as internal standards for ¹H NMR and ¹³C NMR spectra, respectively. The proton spectra are reported as follows δ (position of proton, multiplicity, coupling constant *J*, number of protons). Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), p (quintet), h (septet), m (multiplet) and br (broad). High resolution mass spectra (HRMS) were recorded on quadrupole time-of-flight mass spectrometer (QTOF-MS) using electrospray ionization (ESI) as an ionization method.

2. Synthesis of Preparation of Tetracyclic Core Structure (18)

ethyl 2-(2-(4-bromopyridin-2-yl)-1H-indol-3-yl) acetate (**11**)




To a solution of (*E*)-ethyl-2-aminocinnamate (**9**) (4.8 g, 25 mmol) in anhydrous THF (250 mL) were added aldehyde **10** (4.7 g, 25 mmol), Na₂SO₄ (7.5 g) and MgSO₄ (7.5 g) at room temperature. The mixture was stirred at room temperature and monitored by ¹H NMR analysis of the crude mixture. After the complete conversion of amine **9** and aldehyde **10** into aldimine **I**, the reaction mixture was filtered to remove MgSO₄ and Na₂SO₄. The filtrate was concentrated in vacuo to furnish the crude product of aldimine **I**, which was used in the next step without further purification.

To a solution of the crude mixture in anhydrous DMF (250 mL) were added NaCN (120 mg; 2.5 mmol) and 4 Å molecular sieves (7.5 g) at room temperature. After the complete consumption of aldimine **I**, the reaction mixture was filtered to remove molecular sieves and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate:hexanes = 1:7) to afford indole **11** as a pale yellow solid (8.2 g, 23 mmol, 92%).

Compound 11: ¹H NMR (500 MHz, CDCl₃, ppm) δ 9.40 (br, 1H), 8.45 (dd, *J* = 5.3, 0.4 Hz, 1H), 8.23 (d, *J* = 1.4 Hz, 1H), 7.73 (dd, *J* = 8.1, 0.8 Hz, 1H), 7.42 - 7.36 (m, 2H), 7.28 - 7.26 (m, 1H), 7.17 (ddd, *J* = 7.9, 7.0, 0.9 Hz, 1H), 4.19 (q, *J* = 7.2 Hz, 2H), 4.05 (s, 2H), 1.28 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃, ppm) δ = 171.5, 151.6, 150.2, 135.6, 133.6, 132.6, 129.6, 125.2, 124.7, 124.2, 120.3, 119.8, 111.5, 108.2, 61.3, 31.6, 14.4; HRMS (ESI) calcd for C₁₇H₁₆BrN₂O₂ 359.0395, found 359.0401.


2-(2-(4-bromopyridin-2-yl)-1H-indol-3-yl)ethan-1-ol (**12**)



To a solution of the indole **11** (8.2 g, 23 mmol) in anhydrous THF (240 mL) was slowly added L-selectride solution (71 mL, 1.0 M THF solution) at 0 °C. The mixture was stirred and monitored by TLC. After the complete consumption of indole **11**, the reaction mixture was quenched with water and stirred vigorously for 15 min. The crude mixture was extracted with ethyl acetate. The organic layers were combined, dried over MgSO₄ and concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate:hexanes = 1:2) to afford alcohol **12** as a white solid (5.3 g, 22 mmol, 96%).

Compound 12: ¹H NMR (500 MHz, CDCl₃, ppm) δ 9.13 (br, 1H), 8.35 (dd, *J* = 5.3, 0.3 Hz, 1H), 7.89 (d, *J* = 1.4 Hz, 1H), 7.59 (d, *J* = 7.9 Hz, 1H), 7.33 - 7.28 (m, 2H), 7.20 (ddd, *J* = 8.2, 7.0, 1.1 Hz, 1H), 7.10 (ddd, *J* = 8.0, 7.0, 1.0 Hz, 1H), 4.08 (t, *J* = 6.1 Hz, 2H), 4.00 (br, 1H), 3.33 (t, *J* = 6.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃, ppm) δ 151.9, 149.5, 136.4, 133.8, 132.3, 129.2, 125.1, 124.3, 124.2, 120.1, 119.5, 114.2, 111.6, 63.4, 27.8; HRMS (ESI) calcd for C₁₅H₁₄BrN₂O 317.0290, found 317.0286.


2-bromo-7,12-dihydro-6H-indolo[2,3-a]quinolizin-5-ium trifluoromethanesulfonate (13)



To a solution of alcohol **12** (5.0 g, 21 mmol) and triethylamine (4.4 mL, 32 mmol) in dry CHCl_3 (210 mL) at room temperature was slowly added trifluoromethanesulfonic anhydride (5.3 mL, 25 mmol). After stirring for 15 min, the resulting yellow precipitate was collected by filtration and washed with CHCl_3 . The yellow solid was identified as compound **13** (8.7 g, 19 mmol, 88%).

Compound 13: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 12.23 (s, 1H), 8.82 (d, $J = 6.7$ Hz, 1H), 8.54 (d, $J = 2.1$ Hz, 1H), 8.11 (dd, $J = 6.7, 2.1$ Hz, 1H), 7.74 (d, $J = 8.10$ Hz, 1H), 7.56 (d, $J = 8.40$ Hz, 1H), 7.40 (ddd, $J = 8.2, 7.0, 1.1$ Hz, 1H), 7.19 (ddd, $J = 8.0, 7.0, 0.8$ Hz, 1H), 4.82 (t, $J = 7.4$ Hz, 2H), 3.38 (t, $J = 7.4$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 145.9, 143.3, 141.3, 139.6, 126.8, 126.1, 124.6, 124.3, 123.7, 121.0, 120.9, 118.8, 112.7, 55.3, 18.8; HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{BrN}_2$ 299.0178, found 299.0179.

methyl 2-(1,4,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-2-yl)acetate (15)



To a solution of compound **13** (8.6 g, 19 mmol) and Meldrum's acid (3.6 g, 25 mmol) in anhydrous THF (190 mL) was added triethylamine (6.7 mL, 47 mmol). The mixture was stirred at room temperature and monitored by TLC. After the complete consumption of the starting material **13**, the reaction mixture was quenched with water and stirred for 30 min. The crude mixture was extracted with ethyl acetate. The organic layers were combined, dried over MgSO_4 and concentrated *in vacuo* to furnish the crude product of the compound. Without complete isolation, the crude mixture was used in the next step.


To a solution of the crude mixture of compound in anhydrous MeOH (190 mL) were added HCl (61 mL, 1.25 M solution in MeOH). The reaction mixture was stirred at 60 °C and monitored by TLC. After the complete consumption of starting material, the reaction mixture was cooled to room temperature and concentrated *in vacuo*. The resulting crude mixture **14** was used in the next step without purification.

To a solution of the crude mixture of compound **14** in MeOH (190 mL) was added NaBH_4 (2.2 g, 57 mmol) in three portions. The mixture was stirred at room temperature and monitored by TLC. After the complete consumption of the starting material **14**, the reaction mixture was quenched with water and stirred for 15 min and diluted with ethyl acetate. The crude mixture was extracted with ethyl acetate. The organic layers were combined, dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by column chromatography (100% ethyl acetate) to afford **15** as a white solid (4.0 g, 14 mmol, 70%).

Compound 15: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 7.80 (br, 1H), 7.50 (d, $J = 7.8$ Hz, 1H), 7.37 - 7.28 (m, 1H), 7.15 (td, $J = 7.5, 1.3$ Hz, 1H), 7.13 - 7.08 (m, 1H), 5.70 (dd, $J = 2.6, 1.1$ Hz, 1H), 3.71 (s, 3H), 3.63 - 3.57 (m, 1H), 3.53 - 3.45 (m, 1H), 3.19 (dd, $J = 11.4, 4.7$ Hz, 1H), 3.11 (t, $J = 14.6$ Hz, 3H), 3.04 - 2.97 (m, 1H), 2.80 - 2.73 (m, 1H), 2.65 (td, $J = 11.4, 4.1$ Hz, 1H), 2.56 (d, $J = 16.5$ Hz, 1H), 2.39 - 2.30 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 171.9, 136.4, 134.6, 128.8, 127.3,

124.6, 121.7, 119.6, 118.4, 110.9, 108.7, 55.5, 54.5, 52.1, 52.1, 42.3, 34.4, 21.6; **HRMS (ESI)** calcd for C₁₈H₂₁N₂O₂ 297.1603, found 297.1608.


tert-butyl 2-(2-methoxy-2-oxoethyl)-1,3,4,6,7,12*b*-hexahydroindolo[2,3-*a*]quinolizine-12(2*H*)-carboxylate (**16**)



The starting material **15** (89 mg, 0.30 mmol) was dissolved in EtOH (130 mL) and Pd/C (32 mg, 10 wt%) was added to the reaction mixture. The above mixture was stirred at room temperature under a hydrogen atmosphere and monitored by TLC. After complete consumption of compound **15**, the reaction mixture was filtered in celite to remove an insoluble solid. Then, the filtrate was concentrated, and the crude mixture was purified by column chromatography on silica (diethylether:MeOH = 20:1 to 10:1) to afford **16** as transparent oil (86 mg, 29 mmol, 96%).

Compound 16: ¹H NMR (500 MHz, CDCl₃, ppm) δ 7.76 (br, 1H), 7.49 - 7.44 (m, 1H), 7.30 (d, *J* = 7.93 Hz, 1H), 7.13 (td, *J* = 7.52, 1.14 Hz, 1H), 7.10 - 7.05 (m, 1H), 3.72 (s, 3H), 3.28 (dd, *J* = 11.37, 1.91 Hz, 1H), 3.12 - 3.04 (m, 2H), 3.04 - 2.96 (m, 1H), 2.77 - 2.68 (m, 1H), 2.62 (td, *J* = 11.33, 4.35 Hz, 1H), 2.46 (td, *J* = 11.90, 2.75 Hz, 1H), 2.41 - 2.27 (m, 2H), 2.24 - 2.17 (m, 1H), 2.15 - 2.04 (m, 1H), 1.85 - 1.75 (m, 1H), 1.53 (qd, *J* = 12.51, 4.27 Hz, 1H), 1.33 (q, *J* = 11.80 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃, ppm) δ 173.2, 136.1, 134.7, 127.6, 121.5, 119.5, 118.3, 110.9, 108.4, 59.6, 55.4, 53.3, 51.8, 41.1, 36.2, 33.2, 32.2, 21.9; **HRMS (ESI)** calcd for C₁₈H₂₃N₂O₂ 299.1760, found 299.1758.


tert-butyl 2-(2-methoxy-2-oxoethyl)-1,6,7,12*b*-tetrahydroindolo[2,3-*a*]quinolizine-12(4*H*)-carboxylate (**17**)



To a solution of compound **15** (4.0 g, 14 mmol), Boc₂O (4.6 g, 21 mmol) and DMAP (510 mg, 4.2 mmol) in acetonitrile (140 mL) was added TEA (2.9 mL, 21 mmol) at room temperature. The reaction mixture was stirred at room temperature and monitored by TLC. After the complete conversion of starting material **15**, the reaction mixture was concentrated *in vacuo*, quenched with water and extracted with ethyl acetate. The organic layers were combined, dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (ethyl acetate:hexanes = 1:2) to afford compound **17** as a yellow solid (5.3 g, 13 mmol, 95%).

Compound 17: ¹H NMR (500 MHz, CDCl₃, ppm) δ 8.07 (d, *J* = 8.2 Hz, 1H), 7.46 - 7.39 (m, 1H), 7.29 - 7.26 (m, 1H), 7.24 - 7.20 (m, 1H), 5.71 - 5.63 (m, 1H), 4.23 - 4.16 (m, 1H), 3.67 (s, 3H), 3.52 - 3.37 (m, 2H), 3.17 - 3.08 (m, 1H), 3.03 (s, 2H), 2.88 (dtd, *J* = 9.7, 4.9, 4.9, 2.8 Hz, 1H), 2.79 - 2.71 (m, 2H), 2.66 (d, *J* = 16.8 Hz, 1H), 2.21 (d, *J* = 2.4 Hz, 1H), 1.66 (s, 9H); ¹³C NMR (125 MHz, CDCl₃, ppm) δ 171.8, 150.5, 137.0, 136.9, 129.6, 129.4, 124.1, 123.6, 122.8, 118.2, 116.4, 115.6, 84.0, 56.0, 54.5, 51.9, 48.4, 42.8, 33.5, 28.3, 22.4; **HRMS (ESI)** calcd for C₂₃H₂₉N₂O₄ 397.2127, found 397.2124.

tert-butyl 2-(2-methoxy-2-oxoethyl)-1,3,4,6,7,12*b*-hexahydroindolo[2,3-*a*]quinolizine-12(2*H*)-carboxylate (**18**)




The starting material **17** (5.3 g, 13 mmol) was dissolved in EtOH (130 mL) and Pd/C (1.4 g, 10 wt%) was added to the reaction mixture. The above mixture was stirred at room temperature under a hydrogen atmosphere and monitored by TLC. After complete consumption of compound **17**, the reaction mixture was filtered in celite to remove an insoluble solid. Then, the filtrate was concentrated, and the crude mixture was purified by column chromatography on silica (diethylether:MeOH:acetone = 200:1:1 to 100:1:1) to afford **18** (4.5 g, 11 mmol, 85%) and 15-*epi*-**18** (730 mg, 1.8 mmol, 14%) as yellowish oil.

Compound 18: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 7.92 (dd, $J = 7.3, 0.9$ Hz, 2H), 7.42 - 7.38 (m, 2H), 7.26 - 7.18 (m, 5H), 4.26 (d, $J = 9.6$ Hz, 1H), 3.71 (s, 3H), 3.20 - 3.13 (m, 1H), 3.00 - 2.94 (m, 1H), 2.93 - 2.84 (m, 2H), 2.84 - 2.76 (m, 1H), 2.71 - 2.60 (m, 3H), 2.45 - 2.38 (m, 1H), 2.06 - 1.96 (m, 2H), 1.84 (dd, $J = 10.1, 4.5$ Hz, 1H), 1.66 (s, 9H), 1.43 (d, $J = 13.6$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 173.6, 150.5, 137.7, 136.4, 129.5, 123.7, 122.5, 118.0, 116.3, 115.3, 83.6, 54.6, 51.5, 50.2, 48.5, 36.5, 33.2, 29.0, 28.2, 27.7, 21.8; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{31}\text{N}_2\text{O}_4$ 399.2284, found 399.2282.

Compound 15-*epi*-18: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 8.10 (d, $J = 8.1$ Hz, 1H), 7.40 (dd, $J = 7.5, 0.8$ Hz, 1H), 7.28 - 7.24 (td, $J = 8.4, 1.5$ Hz, 1H), 7.21 (td, $J = 7.4, 1.1$ Hz, 1H), 4.06 (d, $J = 10.5$ Hz, 1H), 3.67 (s, 3H), 3.16 - 3.10 (m, 2H), 2.92 (td, $J = 12.7, 2.9$ Hz, 1H), 2.87 - 2.79 (m, 1H), 2.79 - 2.69 (m, 2H), 2.31 - 2.21 (m, 2H), 2.20 - 2.13 (m, 2H), 1.67 (s, 9H), 1.62 (d, $J = 13.0$ Hz, 1H), 1.54 - 1.43 (m, 1H), 1.30 - 1.21 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 173.0, 150.5, 137.0, 137.0, 129.4, 124.1, 122.7, 118.0, 116.1, 115.6, 83.9, 58.9, 55.1, 51.6, 47.3, 41.6, 34.9, 33.8, 29.4, 28.3, 22.5; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{31}\text{N}_2\text{O}_4$ 399.2284, found 399.2281.

3. Total Synthesis of (±)-20-*epi*-Antirrhine (**3**) and (±)-20-*epi*-18,19-Dihydroantirrhine (**4**)


tert-butyl 2-(1-methoxy-1-oxo-4-(phenylsulfinyl)butan-2-yl)-1,3,4,6,7,12*b*-hexahydroindolo[2,3-*a*]quinolizine-12(2*H*)-carboxylate (**19**)



To a flame-dried flask were added compound **18** (120 mg, 0.30 mmol) and distilled THF (3.0 mL). To a solution of mixture was slowly added LiHMDS solution (0.36 mL, 1.0 M THF solution) at -78 °C. The resulting mixture was stirred for 30 minutes. Then, phenyl vinyl sulfoxide (48 μ L, 0.36 mmol) was added dropwise by syringe to the reaction mixture. The reaction mixture was allowed to warm to room temperature, stirred for 5 hours. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica (diethyl ether:MeOH = 50:1 to 20:1) to afford the **19** (50 mg, 0.091 mmol, 30%, 44% de) and the starting material **18** (61 mg, 0.15 mmol, 50%).

Compound 19: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 7.94 (d, J = 8.09 Hz, 1H), 7.63 (dd, J = 7.71, 1.75 Hz, 2H), 7.54 - 7.48 (m, 3H), 7.40 (d, J = 7.32 Hz, 1H), 7.28 - 7.19 (m, 2H), 4.37 (d, J = 7.17 Hz, 1H), 3.65 (s, 2.16H), 3.63 (s, 0.84H)*, 3.22 - 3.14 (m, 1H), 3.03 - 2.92 (m, 3H), 2.90 - 2.79 (m, 3H), 2.77 - 2.62 (m, 2H), 2.47 (br, 0.28H)*, 2.41 - 2.32 (m, 0.72H), 2.17 - 2.07 (m, 1H), 2.07 - 1.82 (m, 4H), 1.72 (s, 2.52H)*, 1.71 (s, 6.48H), 1.29 - 1.22 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 175.3, 175.2, 150.7, 150.7, 144.4, 144.3, 137.1, 136.4, 136.3, 131.2, 131.0, 129.6, 129.3, 129.3, 124.2, 124.0, 124.0, 122.7, 118.1, 116.7, 115.6, 115.5, 84.2, 84.1, 55.9, 55.8, 54.3, 54.2, 51.7, 51.7, 50.1, 49.8, 48.0, 46.2, 35.0, 34.7, 29.9, 29.7, 28.4, 27.0, 23.7, 23.7, 21.5, 21.2; HRMS (ESI) calcd for $\text{C}_{31}\text{H}_{39}\text{N}_2\text{O}_5\text{S}$ 551.2580, found 551.2575.


*methyl 2-(1,2,3,4,6,7,12,12*b*-octahydroindolo[2,3-*a*]quinolizin-2-yl)-4-(phenylsulfinyl)butanoate*



To a solution of compound **19** (110 mg, 0.20 mmol) was added formic acid (2.0 mL). To a solution of mixture was heated to 40 °C, stirred and monitored by TLC. Upon complete consumption of starting material **19**, the mixture was neutralized with NaOH to pH 7, and extracted with ethyl acetate. The combined organic layers were dried over MgSO_4 and concentrated *in vacuo*. The crude residue was used in the next step without more purification.

Compound A: crude ^1H NMR (500 MHz, CDCl_3 , ppm) δ 9.51 (br, 0.72H), 9.38 (br, 0.28H)*, 7.71 - 7.57 (m, 2H), 7.57 - 7.46 (m, 4H), 7.42 (d, J = 8.09 Hz, 0.72H), 7.39 (d, J = 8.09 Hz, 0.28H)*, 7.18 - 7.12 (m, 1H), 7.12 - 7.07 (m, 1H), 4.34 (br, 1H), 3.62 (s, 0.84H)*, 3.60 (s, 2.16H), 3.29 - 3.22 (m, 1H), 3.17 (t, J = 10.91 Hz, 1H), 3.11 - 2.99 (m, 2H), 2.91 - 2.77 (m, 2H), 2.75 - 2.65 (m, 2H), 2.62 (dd, J = 15.49, 3.28 Hz, 1H), 2.54 (br, 1H), 2.47 - 2.37 (m, 1H), 2.34 - 2.24 (m, 1H), 1.76 - 1.67 (m, 2H), 1.65 - 1.53 (m, 2H), 1.47 - 1.35 (m, 1H); HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{31}\text{N}_2\text{O}_3\text{S}$ 451.2055, found 451.2053.


2-(1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)-4-(phenylsulfinyl)butan-1-ol (**20**)



To a solution of the ester **A** (81 mg, 0.18 mmol) in anhydrous THF (1.8 mL) was slowly added lithium aluminum hydride solution (0.11 mL, 2.4 M hexane solution) at -15 °C. The mixture was stirred and monitored by TLC. After the complete consumption of ester **A**, the reaction mixture was diluted with ether and warmed to 0 °C. Then it was slowly added 10 μ L of water, 10 μ L of 15% *aq.* NaOH and 30 μ L of water again. The reaction mixture stirred at room temperature for 15 minutes and dried over MgSO₄. The resulting suspension was stirred vigorously for 15 minutes and filtered to remove salts. After NMR analysis to determine the diastereomeric ratio (72:28), the crude residue was used in the next step without purification.

Compound 20: crude ¹H NMR (500 MHz, CDCl₃, ppm) δ 9.69 (br, 0.72H), 9.66 (br, 0.28H)*, 7.68 - 7.62 (m, 0.56H)*, 7.58 - 7.53 (m, 1.44H), 7.53 - 7.44 (m, 4H), 7.43 - 7.36 (m, 1H), 7.15 - 7.10 (m, 1H), 7.10 - 7.04 (m, 1H), 4.33 (br, 1H), 3.74 (d, *J* = 4.12 Hz, 0.28H)*, 3.69 (dd, *J* = 10.99, 3.81 Hz, 0.72H), 3.49 (dd, *J* = 10.99, 7.02 Hz, 0.72H), 3.45 (d, *J* = 7.48 Hz, 0.28H), 3.30 - 3.21 (m, 1H), 3.19 - 3.11 (m, 1H), 3.06 - 2.96 (m, 2H), 2.84 - 2.73 (m, 2H), 2.73 - 2.65 (m, 1H), 2.62 (dd, *J* = 15.41, 4.27 Hz, 1H), 2.49 (d, *J* = 12.97 Hz, 1H), 2.24 - 2.07 (m, 1H), 1.80 - 1.62 (m, 2H), 1.60 - 1.49 (m, 2H); **HRMS (ESI)** calcd for C₂₅H₃₁N₂O₂S 423.2106, found 423.2104.


(±)-20-*epi*-antirhine (**3**)



To a solution of the sulfoxide **20** (54 mg, 0.13 mmol) in xylene (240 mL) was stirred at 170 °C and monitored by TLC. After the complete consumption of sulfoxide **20**, the reaction mixture was concentrated in vacuo. The mixture was purified by column chromatography (diethyl ether:MeOH = 10:1) to afford 20-*epi*-antirhine (**3**) (32 mg, 0.11 mmol, 84%). Spectroscopic data were in good agreement with the literature.²

Compound 3: ¹H NMR (500 MHz, CDCl₃, ppm) δ 7.92 (br, 1H), 7.47 (d, *J* = 7.63 Hz, 1H), 7.34 (d, *J* = 7.93 Hz, 1H), 7.17 - 7.12 (m, 1H), 7.12 - 7.07 (m, 1H), 5.66 (dt, *J* = 17.09, 9.84 Hz, 1H), 5.30 (dd, *J* = 10.30, 1.75 Hz, 1H), 5.21 (dd, *J* = 17.09, 1.37 Hz, 1H), 4.15 (br. s., 1H), 3.74 (dd, *J* = 10.68, 5.04 Hz, 1H), 3.47 (dd, *J* = 10.68, 8.09 Hz, 1H), 3.28 - 3.19 (m, 1H), 3.10 - 2.97 (m, 2H), 2.87 - 2.79 (m, 1H), 2.76 - 2.69 (m, 1H), 2.64 (d, *J* = 10.53 Hz, 1H), 2.30 (d, *J* = 4.73 Hz, 1H), 2.08 - 2.01 (m, 1H), 1.91 (ddd, *J* = 13.35, 8.85, 4.04 Hz, 1H), 1.76 (d, *J* = 11.75 Hz, 1H), 1.65 - 1.53 (m, 2H); ¹³C NMR (125 MHz, CDCl₃, ppm) δ 138.2, 136.0, 133.2, 127.7, 121.7, 119.7, 119.2, 118.2, 111.1, 108.1, 63.5, 54.4, 51.9, 49.7, 47.4, 31.5, 31.1, 28.8, 18.7; **HRMS (ESI)** calcd for C₁₉H₂₅N₂O 297.1967, found 297.1964.

(±)-20-*epi*-18,19-dihydroantirrhine (**4**)




The starting material **3** (15 mg, 0.050 mmol) was dissolved in MeOH (0.50 mL), and Pd/C (5.3 mg, 10 wt% on carbon) was added to the reaction mixture. The above mixture was stirred at room temperature under a hydrogen atmosphere and monitored by TLC. After complete consumption of compound **3**, the reaction mixture was filtered in celite to remove an insoluble solid. Then, the filtrate was concentrated, and the crude mixture was purified by column chromatography on silica (diethyl-ether:MeOH = 10:1) to afford **4** (14 mg, 0.049 mmol, 98%). Spectroscopic data were in good agreement with the literature.^{3,4}

Compound 4: ¹H NMR (500 MHz, CDCl₃, ppm) δ 8.12 (br, 1H), 7.47 (d, *J* = 7.63 Hz, 1H), 7.35 (d, *J* = 7.93 Hz, 1H), 7.18 - 7.13 (m, 1H), 7.13 - 7.07 (m, 1H), 4.36 (br, 1H), 3.69 (d, *J* = 5.49 Hz, 2H), 3.32 - 3.24 (m, 1H), 3.17 (td, *J* = 12.32, 5.26 Hz, 1H), 3.03 (dddd, *J* = 15.54, 9.06, 6.14, 3.13 Hz, 1H), 2.85 - 2.79 (m, 1H), 2.77 - 2.71 (m, 1H), 2.63 (dd, *J* = 15.56, 4.43 Hz, 1H), 2.14 (d, *J* = 13.58 Hz, 1H), 1.97 - 1.88 (m, 1H), 1.68 - 1.58 (m, 2H), 1.58 - 1.46 (m, 2H), 1.45 - 1.38 (m, 1H), 1.36 - 1.28 (m, 2H), 0.92 (t, *J* = 7.40 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃, ppm) δ 136.1, 133.0, 127.7, 121.6, 119.6, 118.1, 111.2, 107.8, 62.8, 54.6, 51.5, 46.7, 45.0, 31.7, 30.3, 28.9, 20.4, 17.8, 12.2; HRMS (ESI) calcd for C₁₉H₂₇N₂O 299.2123, found 299.2120.

4. Total Synthesis of (±)-Antirrhine (1) and (±)-18,19-Dihydroantirrhine (2)

tert-butyl 2-(1,3-dimethoxy-1-oxopropan-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate




To a flame-dried flask were added compound **18** (240 mg, 0.60 mmol) and distilled THF (6.0 mL). To a solution of mixture was slowly added LiHMDS solution (0.90 mL, 1.0 M THF solution) at -78 °C. The resulting mixture was stirred for 30 minutes. Then, chloromethyl methyl ether (68 μ L, 0.90 mmol) was added dropwise by syringe to the reaction mixture. The reaction mixture was allowed to warm to room temperature, stirred and monitored by TLC. After the complete consumption of starting material **18**, the mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica (diethyl ether:MeOH = 50:1 to 20:1) to afford **21** (170 mg, 0.38 mmol, 64%) and 20-*epi*-**21** (42 mg, 0.096 mmol, 16%).

Compound 21: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 7.91 (dd, J = 7.40, 1.14 Hz, 1H), 7.42 - 7.38 (m, 1H), 7.26 - 7.19 (m, 2H), 4.40 (d, J = 9.00 Hz, 1H), 3.93 (dd, J = 8.85, 4.27 Hz, 1H), 3.73 (s, 3H), 3.72 - 3.64 (m, 1H), 3.41 (s, 3H), 3.32 (td, J = 10.49, 4.20 Hz, 1H), 3.22 - 3.14 (m, 1H), 3.13 - 3.04 (m, 1H), 2.97 - 2.78 (m, 3H), 2.73 - 2.63 (m, 1H), 2.11 - 2.00 (m, 2H), 1.98 - 1.88 (m, 1H), 1.81 (ddd, J = 13.73, 10.07, 4.12 Hz, 1H), 1.69 (s, 9H), 1.65 (d, J = 3.05 Hz, 1H), 1.32 - 1.26 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 175.4, 150.7, 137.4, 136.3, 129.6, 124.0, 122.8, 118.2, 116.6, 115.5, 83.9, 72.7, 59.0, 54.2, 51.7, 50.3, 47.8, 46.6, 32.4, 30.1, 28.4, 26.6, 21.6; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{35}\text{N}_2\text{O}_5$ 443.2546, found 443.2542.

Compound 20-*epi*-21: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 7.97 - 7.92 (m, 1H), 7.42 - 7.37 (m, 1H), 7.26 - 7.23 (m, 1H), 7.23 - 7.19 (m, 1H), 4.43 - 4.33 (m, 1H), 3.77 (s, 3H), 3.63 - 3.54 (m, 2H), 3.31 (s, 3H), 3.24 - 3.14 (m, 1H), 2.97 - 2.87 (m, 3H), 2.83 (t, J = 5.65 Hz, 2H), 2.65 - 2.56 (m, 1H), 2.06 - 1.96 (m, 3H), 1.85 (td, J = 6.98, 4.20 Hz, 1H), 1.66 (s, 9H), 1.52 (dd, J = 13.50, 5.26 Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 174.4, 150.6, 137.0, 136.8, 129.6, 124.0, 122.7, 118.0, 116.9, 115.5, 83.8, 72.6, 59.2, 55.1, 51.8, 49.1, 49.0, 47.6, 32.0, 31.3, 28.3, 26.7, 20.3; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{35}\text{N}_2\text{O}_5$ 443.2546, found 443.2544.


tert-butyl 2-(1-hydroxy-3-methoxypropan-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate (**22**)



To a solution of compound **21** (170 mg, 0.38 mmol) in distilled THF (3.8 mL) was added DIBAL-H solution (1.1 mmol, 1.0 M THF solution). The mixture was stirred at room temperature and monitored by TLC. After the complete consumption of ester **21**, the reaction mixture was diluted with ether and cooled to 0 °C. Then it was slowly added 48 μ L of water, 48 μ L of 15% *aq.* NaOH and 120 μ L of water again. The reaction mixture was warmed to room temperature and stirred for 15 minutes, dried over MgSO_4 and stirred vigorously for 15 minutes. After filtered to remove salts, the mixture was purified by column chromatography (diethyl ether:MeOH = 5:1) to afford the **22** (150 mg, 0.36 mmol, 95%).

Compound 22: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 7.91 (dd, $J = 7.25, 1.14$ Hz, 1H), 7.42 - 7.38 (m, 1H), 7.26 - 7.19 (m, 2H), 4.36 (d, $J = 7.93$ Hz, 1H), 3.93 - 3.86 (m, 2H), 3.79 - 3.71 (m, 2H), 3.40 (s, 3H), 3.23 - 3.17 (m, 1H), 2.98 - 2.81 (m, 5H), 2.69 - 2.62 (m, 1H), 2.16 (td, $J = 6.22, 3.13$ Hz, 1H), 2.08 - 2.00 (m, 1H), 1.94 - 1.81 (m, 3H), 1.69 (s, 9H), 1.66 - 1.60 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 150.8, 137.8, 136.6, 129.7, 123.9, 122.7, 118.1, 116.9, 115.4, 83.7, 75.7, 65.2, 59.3, 54.8, 50.2, 48.3, 39.4, 30.7, 29.6, 28.4, 25.6, 21.4; **HRMS (ESI)** calcd for $\text{C}_{24}\text{H}_{35}\text{N}_2\text{O}_4$ 415.2597, found 415.2592.


tert-butyl 2-(3-oxoprop-1-en-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-*a*]quinolizine-12(2H)-carboxylate (**B**)



To a solution of compound **22** (150 mg, 0.36 mmol) in distilled DCM (3.6 mL) were added Dess-Martin periodinane (200 mg, 0.46 mmol) and sodium bicarbonate (30 mg, 0.36 mmol) at room temperature. The resulting mixture was stirred at room temperature monitored by TLC. After the complete consumption of starting material **22**, the reaction mixture was quenched with sodium thiosulfate and stirred for 30 minutes. Then the crude mixture was extracted with brine, combined organic layer was dried over MgSO_4 and concentrated in vacuo to furnish the crude product of aldehyde **B**. The mixture was purified by column chromatography (diethyl ether:MeOH = 5:1) to afford the α,β -unsaturated aldehyde **C**.

Compound C: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 9.56 (s, 1H), 7.91 (dd, $J = 7.32, 0.92$ Hz, 1H), 7.43 - 7.38 (m, 1H), 7.26 - 7.19 (m, 2H), 6.83 (d, $J = 1.37$ Hz, 1H), 6.23 (d, $J = 0.76$ Hz, 1H), 4.30 (d, $J = 8.09$ Hz, 1H), 3.18 (dt, $J = 11.25, 4.75$ Hz, 1H), 2.97 - 2.86 (m, 4H), 2.86 - 2.78 (m, 1H), 2.70 - 2.62 (m, 1H), 2.23 (d, $J = 13.73$ Hz, 1H), 2.15 - 2.06 (m, 1H), 2.03 - 1.95 (m, 1H), 1.72 (dt, $J = 12.28, 1.95$ Hz, 1H), 1.66 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 195.1, 152.5, 150.7, 137.5, 136.5, 135.3, 129.6, 123.9, 122.7, 118.2, 116.7, 115.4, 84.0, 55.2, 50.6, 48.5, 31.2, 30.6, 28.4, 26.1, 21.5; **HRMS (ESI)** calcd for $\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}_3$ 381.2178, found 381.2175.

tert-butyl 2-(1-methoxybut-3-en-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-*a*]quinolizine-12(2H)-carboxylate




To a solution of compound **22** (150 mg, 0.36 mmol) in distilled DCM (3.6 mL) were added Dess-Martin periodinane (200 mg, 0.46 mmol) and sodium bicarbonate (30 mg, 0.36 mmol) at room temperature. The resulting mixture was stirred at room temperature monitored by TLC. After the complete consumption of starting material **22**, the reaction mixture was quenched with sodium thiosulfate and stirred for 30 minutes. Then it was extracted with brine and combined organic layer was dried over MgSO_4 and concentrated in vacuo to furnish the crude product of aldehyde **B**, which was used in the next step without further purification.

To a flame-dried flask were added methyltriphenylphosphonium bromide (190 mg, 0.54 mmol), distilled THF (1.0 mL) and LiHMDS solution (0.54 mL, 1.0 M THF solution) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 30 minutes. Meanwhile, the crude mixture of **B** was dissolved in THF (2.6 mL) in a flame-dried round-bottom flask under argon and cooled to -30 °C. The freshly prepared Wittig reagent solution was transferred to the solution of **B** in THF slowly dropwise via syringe, and the mixture was allowed to stir at the same temperature and monitored by TLC. After the complete

consumption of starting material **B**, the mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica (diethyl ether:MeOH = 50:1 to 20:1) to afford the **23** (61 mg, 0.15 mmol, 41%).

Compound 23: ¹H NMR (500 MHz, CDCl₃, ppm) δ 7.93 (dd, *J* = 7.32, 0.92 Hz, 1H), 7.43 - 7.38 (m, 1H), 7.26 - 7.19 (m, 2H), 5.73 - 5.64 (m, 1H), 5.16 - 5.14 (m, 1H), 5.14 - 5.10 (m, 1H), 4.45 (br, 1H), 3.68 (dd, *J* = 9.31, 3.66 Hz, 1H), 3.56 (dd, *J* = 9.16, 7.48 Hz, 1H), 3.40 - 3.35 (m, 3H), 3.26 - 3.18 (m, 1H), 2.99 - 2.79 (m, 4H), 2.77 - 2.64 (m, 2H), 2.09 (d, *J* = 13.58 Hz, 1H), 1.89 - 1.71 (m, 4H), 1.66 - 1.71 (m, 9H), 1.58 (d, *J* = 13.89 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃, ppm) δ 150.7, 140.3, 138.0, 136.6, 129.8, 123.8, 122.7, 118.1, 116.7, 116.4, 115.4, 83.7, 74.7, 58.9, 54.6, 49.8, 48.3, 44.7, 32.4, 30.6, 28.4, 25.8, 21.4; **HRMS (ESI)** calcd for C₂₅H₃₅N₂O₃ 411.2648, found 411.2644.


2-(1-methoxybut-3-en-2-yl)-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine (**24**)



To a solution of compound **23** (44 mg, 0.11 mmol) was added formic acid (1.1 mL). To a solution of mixture was heated to 40 °C, stirred and monitored by TLC. Upon complete consumption of starting material **23**, the mixture was neutralized with NaOH to pH 7, and extracted with ethyl acetate. The combined organic layers were dried over MgSO₄ and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica (diethyl ether:MeOH = 10:1) to afford the **24** (29 mg, 0.094 mmol, 85%).

Compound 24: crude ¹H NMR (500 MHz, CDCl₃, ppm) δ 7.87 (br, 1H), 7.48 (d, *J* = 7.63 Hz, 1H), 7.34 (d, *J* = 7.93 Hz, 1H), 7.16 (td, *J* = 7.55, 1.22 Hz, 1H), 7.13 - 7.08 (m, 1H), 5.70 - 5.60 (m, 1H), 5.12 (dd, *J* = 10.30, 1.91 Hz, 1H), 5.08 (dt, *J* = 17.20, 0.86 Hz, 1H), 4.24 (br, 1H), 3.51 - 3.46 (m, 1H), 3.44 - 3.39 (m, 1H), 3.36 (s, 3H), 3.27 - 3.21 (m, 1H), 3.10 (d, *J* = 4.43 Hz, 1H), 3.03 (ddd, *J* = 15.34, 5.95, 2.52 Hz, 1H), 2.75 (dd, *J* = 9.46, 3.20 Hz, 1H), 2.67 (ddd, *J* = 11.41, 5.30, 3.43 Hz, 1H), 2.64 - 2.58 (m, 1H), 2.34 - 2.26 (m, 1H), 2.09 - 2.01 (m, 1H), 1.96 (dd, *J* = 9.38, 4.35 Hz, 1H), 1.71 - 1.64 (m, 1H), 1.57 - 1.45 (m, 2H); **HRMS (ESI)** calcd for C₂₀H₂₇N₂O 311.2123, found 311.2122.

(±)-antirhine (**1**)




To a flask were added sodium iodide (85 mg, 0.56 mmol), distilled DCM (0.10 mL) and 15-crown-5 (124 mg, 0.56 mmol) at room temperature. The iodide reagent mixture was stirred for 30 minutes. Meanwhile, compound **24** (29 mg, 0.094 mmol) was dissolved in distilled DCM (1.0 mL) under argon and cooled to -30 °C. The freshly prepared reagent iodide solution was transferred to the solution of **24** in DCM rapidly dropwise via syringe. To the reaction mixture was added slowly the boron tribromide solution (0.28 mL, 1.0 M DCM solution) at -30 °C. The reaction mixture was stirred and monitored by TLC. After the complete consumption of starting material **24**, the mixture was quenched with sodium bicarbonate aqueous solution and extracted with DCM. The combined organic layers were dried over MgSO₄ and concentrated *in vacuo*. The crude residue was

purified by column chromatography on silica (diethyl ether:MeOH = 10:1) to afford antirrhine (**1**) (8.3 mg, 0.028 mmol, 30%). Spectroscopic data were in good agreement with the literature.⁵

Compound 1: ¹H NMR (500 MHz, CDCl₃, ppm) δ 7.99 (br, 1H), 7.47 (d, *J* = 7.63 Hz, 1H), 7.33 (d, *J* = 7.78 Hz, 1H), 7.18 - 7.12 (m, 1H), 7.12 - 7.07 (m, 1H), 5.60 (dt, *J* = 17.36, 9.63 Hz, 1H), 5.22 (d, *J* = 10.22 Hz, 1H), 5.16 (d, *J* = 17.09 Hz, 1H), 4.16 (br, 1H), 3.74 (dd, *J* = 10.76, 4.20 Hz, 1H), 3.59 (dd, *J* = 10.45, 7.55 Hz, 1H), 3.25 - 3.17 (m, 1H), 3.10 - 2.96 (m, 2H), 2.81 - 2.72 (m, 1H), 2.69 - 2.56 (m, 2H), 2.25 (br, 1H), 2.10 - 2.02 (m, 1H), 1.97 - 1.89 (m, 1H), 1.71 (d, *J* = 5.95 Hz, 1H), 1.56 - 1.45 (m, 2H); ¹³C NMR (125 MHz, CDCl₃, ppm) δ 138.3, 135.9, 133.7, 127.8, 121.5, 119.6, 118.7, 118.2, 111.1, 108.2, 63.8, 54.5, 52.0, 49.8, 47.2, 31.9, 31.9, 28.9, 18.6; HRMS (ESI) calcd for C₁₉H₂₅N₂O 297.1967, found 297.1964.

(±)-18,19-dihydroantirrhine (**2**)




The starting material **1** (8.3 mg, 0.028 mmol) was dissolved in MeOH (0.30 mL), and Pd/C (3.0 mg, 10 wt% on carbon) was added to the reaction mixture. The above mixture was stirred at room temperature under a hydrogen atmosphere and monitored by TLC. After complete consumption of compound **1**, the reaction mixture was filtered in celite to remove an insoluble solid. Then, the filtrate was concentrated, and the crude mixture was purified by column chromatography on silica (diethyl ether:MeOH = 10:1) to afford 18,19-dihydroantirrhine (**2**) (8.1 mg, 0.027 mmol, 97%). Spectroscopic data were in good agreement with the literature.⁴

Compound 2: ¹H NMR (500 MHz, CDCl₃, ppm) δ 8.21 (br, 1H), 7.46 (d, *J* = 7.63 Hz, 1H), 7.33 (d, *J* = 7.78 Hz, 1H), 7.16 - 7.11 (m, 1H), 7.11 - 7.05 (m, 1H), 4.28 (br, 1H), 3.79 - 3.66 (m, 2H), 3.30 - 3.18 (m, 1H), 3.10 (br, 1H), 3.06 - 2.96 (m, 1H), 2.84 - 2.74 (m, 1H), 2.70 (d, *J* = 11.29 Hz, 1H), 2.60 (dd, *J* = 15.56, 4.27 Hz, 1H), 2.13 (d, *J* = 12.82 Hz, 1H), 1.96 (br, 1H), 1.71 (d, *J* = 10.99 Hz, 1H), 1.56 - 1.41 (m, 3H), 1.37 - 1.20 (m, 3H), 0.90 (t, *J* = 7.32 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃, ppm) δ 136.0, 133.3, 127.7, 121.5, 119.5, 118.1, 111.2, 107.6, 62.3, 54.6, 51.6, 46.9, 44.9, 32.0, 31.6, 28.8, 21.2, 18.0, 12.1; HRMS (ESI) calcd for C₁₉H₂₇N₂O 299.2123, found 299.1758.

5. Syntheses of 20-*epi*-18,19-Dihydroantirrhine (**4**) and 18,19-Dihydroantirrhine (**2**) via Ethylation of Enolate

tert-butyl-2-(1-methoxy-1-oxobutan-2-yl)-1,3,4,6,7,12*b*-hexahydroindolo[2,3-*a*]quinolizine-12(2*H*)-carboxylate (**26**)




To a flame-dried flask were added compound **18** (80 mg, 0.20 mmol) and distilled THF (2.0 mL). To a solution of mixture was slowly added LiHMDS solution (1.0 mL, 1.0 M THF solution) at -78 °C. The resulting mixture was stirred for 30 minutes. Then, iodoethane (80 μ L, 1.0 mmol) was added dropwise by syringe to the reaction mixture, and the mixture was allowed to warm to room temperature, stirred at room temperature and monitored by TLC. Upon complete consumption of starting material **18**, the mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The crude residue was purified by column chromatography on silica (diethyl ether:MeOH = 50:1) to afford compound **26** (54 mg, 0.13 mmol, 64%) and its 20-*epi*-**26** (14 mg, 0.031 mmol, 16%).

Compound 26: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 7.93 - 7.88 (m, 1H), 7.42 - 7.38 (m, 1H), 7.25 - 7.18 (m, 2H), 4.37 - 4.30 (m, 1H), 3.70 (s, 2H), 3.21 - 3.13 (m, 1H), 3.03 - 2.94 (m, 1H), 2.92 - 2.75 (m, 4H), 2.70 - 2.60 (m, 1H), 2.12 - 2.03 (m, 1H), 1.93 (br, 3H), 1.87 - 1.78 (m, 1H), 1.67 (s, 9H), 1.62 - 1.52 (m, 1H), 1.33 - 1.24 (m, 1H), 0.95 (t, J = 7.4 Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 176.8, 150.7, 137.6, 136.5, 129.7, 123.8, 122.7, 118.1, 116.6, 115.3, 83.8, 54.6, 51.3, 50.2, 48.5, 48.3, 34.9, 30.4, 28.3, 27.6, 23.6, 21.5, 12.0.

Compound 20-*epi*-26: ^1H NMR (500 MHz, CDCl_3 , ppm) δ 7.95 (d, J = 8.1 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.26 - 7.18 (m, 2H), 4.41 (br, 1H), 3.77 - 3.72 (m, 1H), 3.74 (s, 3H), 3.24 - 3.18 (m, 1H), 3.26 - 3.17 (m, 1H), 2.97 - 2.90 (m, 2H), 2.82 (d, J = 4.7 Hz, 2H), 2.62 (dt, J = 9.3, 4.3 Hz, 2H), 1.98 (d, J = 5.0 Hz, 2H), 1.93 - 1.80 (m, 2H), 1.68 - 1.64 (m, 9H), 1.49 (d, J = 4.0 Hz, 1H), 0.87 (t, J = 7.5 Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3 , ppm) δ 175.9, 150.6, 137.0, 136.8, 129.6, 124.0, 122.7, 118.0, 116.8, 115.5, 83.7, 55.1, 51.4, 49.0, 48.8, 48.3, 32.9, 32.1, 28.3, 26.3, 23.5, 20.3, 11.3.

20-*epi*-18,19-Dihydroantirrhine (**4**) and 18,19-Dihydroantirrhine (**2**)



To a solution of compound **26** (42.7 mg, 0.10 mmol) was added formic acid (1.0 mL). To a solution of mixture was heated to 40 °C, stirred and monitored by TLC. Upon complete consumption of **26**, the mixture was neutralized with NaOH to pH 7, and extracted with ethyl acetate. The combined organic layers were dried over MgSO_4 and concentrated *in vacuo*. The crude residue was used in the next step without more purification.

To a solution of the crude mixture from the above reaction in anhydrous THF (1.0 mL) was slowly added lithium aluminum hydride solution (0.083 mL, 2.4 M hexane solution) at room temperature. The mixture was stirred and monitored by TLC. After the complete reduction of the ester group, the reaction mixture was diluted with ether and cooled to 0 °C. Then it was slowly added 8.0 μ L of water, 8.0 μ L of 15% *aq.* NaOH and 20 μ L of water again. The reaction mixture stirred at room temperature for 15 minutes and dried over MgSO_4 . The crude residue was purified by column chromatography on silica (diethyl

ether:MeOH = 10:1) to afford 20-*epi*-18,19-dihydroantirhine (**4**) (25 mg, 0.084 mmol, 84% yield over two steps). The spectroscopic data were in good agreement with those in the literature.^{3,4}

With compound 20-*epi*-**26**, 18,19-dihydroantirhine (**2**) was obtained through the same procedure with similar efficiency. The spectroscopic data of the resulting product were in good agreement with those of 18,19-dihydroantirhine (**2**).⁴


6. References

1. Lee, S. J.; Seo, H.-A.; Cheon, C.-H. *Adv. Synth. Catal.* **2016**, *358*, 1566-1570.
2. Weniger, B.; Anton, R.; Varea, T.; Quirion, J.-C.; Bastida, J.; Garcia, R. *J. Nat. Prod.* **1994**, *57*, 287-290.
3. Tietze, L. F.; Bachmann, J.; Wichmann, J.; Zhou, Y.; Raschke T. *Liebigs Ann.* 1997, 881-886.
4. Robert, G. M. T.; Ahond, A.; Poupat, C.; Potier, P.; Jollès, C.; Jousselin, A.; Jacquemin, H. *J. Nat. Prod.* **1983**, *46*, 694-707.
5. Suzuki, T.; Sato, E.; Unno, K.; Kametani, T. *Chem. Pharm. Bull.* **1986**, *34*, 3135-3141.


7. Spectroscopic Data

7-1. NMR Spectra of ethyl 2-(2-(4-bromopyridin-2-yl)-1H-indol-3-yl) acetate (**11**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-2. NMR Spectra of 2-(2-(4-bromopyridin-2-yl)-1H-indol-3-yl)ethan-1-ol (**12**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-3. NMR Spectra of 2-bromo-7,12-dihydro-6H-indolo[2,3-a]quinolizin-5-ium trifluoromethanesulfonate (**13**)

a) ^1H NMR Spectrum (in DMSO-d_6 , 500 MHz)




b) ^{13}C NMR Spectrum (in DMSO-d_6 , 125 MHz)




7-4. NMR Spectra of methyl 2-(1,4,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-2-yl)acetate (**15**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-5. NMR Spectra of methyl 2-(1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)acetate (**16**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-6. NMR Spectra of tert-butyl 2-(2-methoxy-2-oxoethyl)-1,6,7,12b-tetrahydroindolo[2,3-a]quinolizine-12(4H)-carboxylate (**17**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-7. NMR Spectra of 2,12b-*trans*-*tert*-butyl 2-(2-methoxy-2-oxoethyl)-1,3,4,6,7,12b-hexahydroindolo[2,3-*a*]quinolizine-12(2H)-carboxylate (**18**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-8. NMR Spectra of 2,12b-*cis*-tert-butyl 2-(2-methoxy-2-oxoethyl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate (15-*epi*-**18**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-9. NMR Spectra of tert-butyl 2-(1-methoxy-1-oxo-4-(phenylsulfinyl)butan-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinoline-12(2H)-carboxylate (**19**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-10. NMR Spectra of methyl 2-(1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)-4-(phenylsulfinyl)butanoate (**A**)

a) crude ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




7-11. NMR Spectra of 2-(1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)-4-(phenylsulfinyl)butan-1-ol (**20**)

a) crude ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




7-12. NMR Spectra of (±)-20-*epi*-antirrhine (**3**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-13. NMR Spectra of (±)-20-*epi*-18,19-dihydroantirrhine (**4**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-14. NMR Spectra of tert-butyl 2-(1,3-dimethoxy-1-oxopropan-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate (**21**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-15. NMR Spectra of tert-butyl 2-(1,3-dimethoxy-1-oxopropan-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate (20-*epi*-**21**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-16. NMR Spectra of tert-butyl 2-(1-hydroxy-3-methoxypropan-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate (**22**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-17. NMR Spectra of tert-butyl 2-(3-oxoprop-1-en-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate (**C**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-18. NMR Spectra of tert-butyl 2-(1-methoxybut-3-en-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate (**23**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-19. NMR Spectra of 2-(1-methoxybut-3-en-2-yl)-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine (**24**)

a) crude ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




7-20. NMR Spectra of (±)-antirrhine (**1**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-21. NMR Spectra of (±)-18,19-dihydroantirrhine (**2**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)




7-22. NMR Spectra of tert-butyl-2-(1-methoxy-1-oxobutan-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate (**26**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)




b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)



7-23. NMR Spectra of tert-butyl-2-(1-methoxy-1-oxobutan-2-yl)-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizine-12(2H)-carboxylate (20-*epi*-**26**)

a) ^1H NMR Spectrum (in CDCl_3 , 500 MHz)



b) ^{13}C NMR Spectrum (in CDCl_3 , 125 MHz)

